Imbio

In December 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio’s regulatory-cleared solutions aim to transform the way patients are discovered, diagnosed, and treated, enabling physician productivity and more personalized care for patients. 

Imbio products, including Lung Density Analysis™ and RV/LV Analysis™, utilize advanced AI algorithms for in-depth analysis of medical images. 

Imbio technologies offer precise and reproducible assessments that can impact treatment planning and patient outcomes.

By leveraging sophisticated texture mapping algorithms and segmentation techniques, Imbio enhances the detection and monitoring of diseases such as Chronic Obstructive Pulmonary Disease (COPD), fibrosis, interstitial lung disease (ILD), and lung cancer.  

Modalities